The Future Of Obesity Treatment: Terns Pharmaceuticals Joins The Race For Oral Weight-Loss Drugs
Terns Pharmaceuticals recently reported promising results for its oral obesity drug, TERN-601, which showed a 4.9% reduction in body weight in an early-stage study. This marks another significant step in the development of oral treatments for obesity, as pharmaceutical companies increasingly shift their focus to more convenient alternatives to injectable medications. The results propelled Terns’…









